Pharmacology

#In vivo #Pharmacology #Sygnature Discovery

Sygnature Discovery appoints new Head of In Vivo Pharmacology 

CRO Sygnature Discovery has announced the appointment of Susanne Back as Head of In Vivo Pharmacology.  Back has 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River. She will lead one of Sygnature’s in vivo pharmacology… Read More

#News

Mouse in laboratory
#Clinical trials #Drug toxicity #Mouse models #Pharmacology #Preclinical investigations #Whitepaper

Whitepaper: Ensure accurate dose prediction for clinical trials

Accurate dose prediction for clinical trials is essential to ensure patient safety and trial success. This new whitepaper from the Jackson Laboratory discusses evidence-based selection of starting doses in first-in-human clinical trials through the utilisation of humanised mouse models. In this whitepaper you will learn about: The significance… Read More

#News

#Clinical trials #Drug toxicity #Mouse models #Pharmacology #Preclinical investigations

Discover evidence-based, first-in-human dose selection

This whitepaper discusses evidence-based selection of starting doses in first-in-human clinical trials through the utilisation of humanised mouse models and emphasises the importance of accurate dose prediction to ensure patient safety and trial success. In this whitepaper you will learn about: The significance of selecting appropriate starting doses in clinical… Read More

#Resources

Drug discovery illustration
#Covid-19 #Drug repositioning #Drug repurposing #Events #Paediatrics #Pharmacology #Rare disease #World Congress of Basic & Clinical Pharmacology

Drug repurposing: The benefits, risks and what we learned from Covid-19

What are benefits of drug repurposing and why do clinical drug trials so often fail? Diana Spencer summarises the key messages from the ‘Drug Repurposing: Challenges and Opportunities’ Symposium held at the 19th World Congress of Basic & Clinical Pharmacology (WCP) 2023. The Drug Repurposing symposium at WCP 2023 was… Read More

#Exclusive Content

#Biotechnology #cryo-microscopy #Drug targets #Pharmacology

Salipro successfully extracts PANX1 membrane protein

Salipro Biotech, in collaboration with AstraZeneca, has published data from a study which describes a novel method to directly extract membrane proteins from cells into lipid Salipro nanoparticles, enabling structure-function analysis using surface plasmon resonance (SPR) and cryo-electron microscopy (cryo-EM) for challenging drug targets. The scientists extracted and… Read More

#News

#Biologics / Biotechnology #CAR-T #China #CRISPR #Drug discovery #Gene editing #Genetics / genomics #HIV #HPV #Oncology #Pharmacology #T cell activation #The Dose

The Dose: DDW’s drug discovery highlights

DDW highlights the most interesting global news and comments within the drug discovery and development sector this month.   Everyone enjoys a good news story and the drug discovery and development sector is no exception. Seeing tangible results of drug efficacy or therapeutics programmes can take years so it was heartening… Read More

#Exclusive Content

Students on the Clinical Pharmacology course
#Clinical pharmacology #Education #Pharmacology

Preparing the next generation of drug discovery scientists

After just one cohort of students, the Clinical Pharmacology degree at St George’s University has been named the UK’s best pharmacology course. DDW’s Diana Spencer speaks to Co-Director Iain Greenwood to find out why a new course was needed and what makes this one unique. St George’s, University of London’s… Read More

#Exclusive Content

#Biotechnology #Drug discovery #Life sciences #Pharmacology

What’s interesting about Australian drug discovery? 

Australia’s drug discovery industry shows promise and innovation, as well as business opportunities. DDW’s Megan Thomas takes a look at some of the reasons why we should be keeping an interested eye on the developments coming out of this country.   The Sector Snapshot 2022: Expansion is continuous   The Sector Snapshot… Read More

#Exclusive Content #Market Reports #Trends & Analysis

#Drug discovery #ELRIG #Events #Pharmacology

Event: New modalities in pharmacology and drug discovery

On 4 and 5 July 2022, The British Pharmacological Society and ELRIG UK will explore new pharmacological modalities of differing mechanisms, shapes and sizes and how these are being translated to create patient benefit at the Francis Crick Institute in London, UK. This is both a free and in-person event. Read More

#News

Knee pain
#Arthritis #Chronic pain #Pharmacology

Altasciences and Virpax conduct first-in-human study of chronic pain

Virpax Pharmaceuticals has chosen Altasciences to conduct a first-in-human study of Epoladerm (diclofenac epolamine) for chronic pain associated with osteoarthritis of the knee. This treatment is supplied in a pre-filled device for administration as a topical spray film.  The study  The study will be conducted in the second quarter of 2022… Read More

#News

#Biotechnology #Clinical trials #Covid-19 #Drug discovery #Pharmaceuticals #Pharmacology

Apeiron Biologics begins Covid-19 trial for inhaled drug candidate

Apeiron Biologics has begun a Phase I trial for inhalation of APN01, a recombinant human angiotensin-converting enzyme 2 developed to treat Covid-19 patients by neutralising SARS-CoV-2 in the lungs and mitigating lung damage caused by the infection.   The double-blind, placebo-controlled, dose-escalation study plans to enroll about 40 healthy volunteers in Austria… Read More

#News

#Academic #Analysis #Assay development optimisation & technology #Cell culture #Cellular assays #Chemistry #Drug discovery #Drug targets #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Medicinal chemistry #PCR #Pharmacology #RNA #Screening #Stem cells #System biology

Guidelines & Recommendations For Analyzing and Interpreting GPCR Second Messenger Data

Guidelines & Recommendations For Analyzing and Interpreting GPCR Second Messenger Data Sponsored by CisBio The question of choosing which methods to use for analyte quantification (signal vs concentration determination, parameters, and format) continues to generate heated debates and divergent understanding. Today, there is still a communication gap between researchers depending… Read More

#Archive

#Business #Drug development #Drug discovery #Pharmacology #Pharmokinetics #Screening

The Kinetics of Drug-Receptor Binding: Why it is important and how we can measure it?

The Kinetics of Drug-Receptor Binding: Why it is important and how we can measure it? Sponsored by BMGLabtech & CISBio Optimizing the receptor binding kinetics of new drugs can have significant benefits, ranging from improved duration of action to enhanced efficacy through the… Read More

Webinar date:
Sponsored by BMG Labtech & CISBio
#Webinars

#Academic #Analysis #Animal models #Assay development optimisation & technology #Biomarkers #Business #Cellular assays #Drug development #Drug discovery #Drug targets #Flow Cytometry #High Content Screening #High throughput screening #Immunology #Lead discovery #Pharmacology #RNA #Screening #Stem cells #Therapeutics #Toxicology

Advanced Therapeutic Antibody Discovery with Multiplexed Screening

Advanced Therapeutic Antibody Discovery with Multiplexed Screening Sponsored by Sartorius Antibody-based therapeutics are the fastest growing and most successful therapeutic modality for treating diseases such as cancer, cardiovascular disease, autoimmune disorders and infectious disease. It is predicted that by the year 2020 there will be 70 therapeutic antibodies on the… Read More

#Archive

#Animal models #Clinical specialities #Lead discovery #Pharmacology #Translational #Translational chemistry

RenaSci bolsters kidney disease and fibrosis capabilities with senior appointment

Leading in vivo pharmacology and consultancy services firm RenaSci, part of the Sygnature Group, have bolstered their Kidney Disease and Fibrosis capabilities with the appointment of Dr Wioletta Pijacka. Wioletta is an in vivo translational biologist with over 12 years of experience in renal and cardio-vascular… Read More

#News

#Drug development #Drug discovery #Drug targets #Immunology #Lead discovery #Oncology #Pathology #PCR #Pharmacology #Protein chemistry / Proteomics #RNA #Stem cells #Therapeutics #Translational #Translational chemistry

Pathios Therapeutics closes US$8.8M Series A and appoints Stuart Hughes as CEO

The financing will accelerate the development of first-in-class therapies in autoimmune disease and immuno-oncology. Pathios Therapeutics Limited (“Pathios”), an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and cancer, today announced a US$8.8M Series A financing round with leading international healthcare… Read More

#News